Ilumya Becomes Sun's New Branded Specialty Drug Pillar

FDA approved Ilumya for moderate to severe plaque psoriasis, furthering the competitive dynamics in the crowded psoriasis market, and establishing the biologic as a major pillar of Sun's new branded specialty drug business.

Pillars with Vintage Style Filter and Sunlight

Sun Pharmaceutical Industries Ltd. is breaking into the branded biologics space in a competitive therapeutic category – plaque psoriasis – dominated by power players like AbbVie Inc., Johnson & Johnson and Novartis AG. The company announced March 21 that the US FDA approved Ilumya (tildrakizumab-asmn) - the company's first biologic - for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ilumya binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor, inhibiting the release of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip